Summit's focus over the next three years or so will be to wrap up its two late-stage clinical programs for treating certain patient populations with advanced or metastatic non-small cell lung cancer (NSCLC) in combination with other treatments like chemotherapy and attempt to get regulators on board with commercializing them.
One of the trials is slated to end in late 2025, and the other is scheduled to conclude in late 2027. If the Food and Drug Administration (FDA) staff assent to either program, it'll mark the first time that the biotech will have an opportunity to generate revenue from sales of a medicine, which will be a major achievement.
Market Data 
Markets 
AI
